Tag:
Curis
Latest Headlines
Latest Headlines
Roche wins landmark approval for targeted cancer drug vismodegib
Roche ( $RHHBY ) and Genentech won a landmark approval for the cancer drug vismodegib today. After gaining significant efficacy data from a Phase II study on basal cell carcinoma, the drug giant not
4SC surges on positive midstage data for advanced liver cancer
Shares of Germany's 4SC ( $VSC ) surged 35% after investigators reported promising mid-stage data for the cancer drug resminostat, an HDAC inhibitor, in difficult-to-treat patients with advanced liver
Curis gets $4M for blood cancer therapy
The Leukemia & Lymphoma Society (LLS) has handed Lexington, MA-based Curis $4 million to support early development of two of the company's drugs for blood cancers. Curis' drug, CUDC-907, is an
Roche preps vismodegib app with "profound" efficacy data
Armed with positive data from a pivotal Phase II trial, Lexington, MA-based Curis is waiting for its partner Roche to begin its long-awaited pitch to gain FDA approval for a new treatment for
Roche preps vismodegib app after Ph2 skin cancer success
Roche and Genentech have posted a fresh set of promising mid-stage data on vismodegib , a cancer drug it's collaborating on with Lexington, MA-based Curis. In what investigators describe as a pivotal
Roche tees up new app on promising Ph2 cancer drug
Lexington, MA-based Curis ( $CRIS ) is eagerly spreading the news that its partners at Roche/Genentech have wrapped a positive mid-stage trial for an experimental new treatment for advanced basal cell
Shulman: Best biotech stocks to own
This morning, MarketWatch's Michael Shulman listed some of what he sees are the hottest bargain biotech stocks for this year: Cerus, Curis, Compugen, Spectrum Pharmaceuticals and Impax Laboratories.
Curis shares sink as Genentech evaluates lead drug's fate
Investigators at Roche and Genentech are preparing an in-depth analysis of a fresh crop of mid-stage data on Curis's GDC-0449 , with an eye to determine whether the therapy should make the cut for
Curis shares plunge after lead drug flunks cancer trial
Cambridge, MA-based Curis ( CRIS ) has been handed a significant setback on its lead cancer program. The developer announced this morning that GDC-0449 flunked the primary endpoint in a Phase II
Curis gets $8M milestone from Debiopharm
Curis will receive $8 million in milestone payments from its Swiss partner Debiopharm after French authorities approved a CTA for a study of Debio 0932, a potential treatment for tumors. Debiopharm
